LEO Pharma Fights Tolmar's Taclonex ANDA

Law360, New York (August 26, 2010, 2:00 PM EDT) -- Danish pharmaceutical company LEO Pharma A/S has lodged a patent infringement suit in an effort to prevent Tolmar Inc. from selling a generic version of Taclonex ointment, which is used to treat the skin disease psoriasis vulgaris.

The suit, filed Wednesday in the U.S. District Court for the District of Delaware, alleges that Fort Collins, Colo.-based Tolmar committed an act of infringement by submitting an abbreviated new drug application for generic Taclonex to the U.S. Food and Drug Administration.

According to the complaint, Tolmar notified LEO...
To view the full article, register now.